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Introduction {#ehf212228-sec-0005}
============

Chronic obstructive pulmonary disease (COPD) is present in approximately one‐third of patients with heart failure (HF) and reduced ejection fraction (HFrEF).[1](#ehf212228-bib-0001){ref-type="ref"} Because of concern regarding respiratory deterioration, COPD is an important cause of underuse and underdosing of β‐blockers.[1](#ehf212228-bib-0001){ref-type="ref"}, [2](#ehf212228-bib-0002){ref-type="ref"}, [3](#ehf212228-bib-0003){ref-type="ref"}, [4](#ehf212228-bib-0004){ref-type="ref"} The mechanistic relationship between COPD and HFrEF is complex, multifactorial, and not fully understood. Hyperinflation and greater changes in intrathoracic pressure during respiration might enhance ventricular pre‐load and afterload, resulting in left ventricular (LV) dysfunction and HF.[5](#ehf212228-bib-0005){ref-type="ref"} Despite increasing evidence that β‐blockers are safe and beneficial in patients with COPD,[6](#ehf212228-bib-0006){ref-type="ref"}, [7](#ehf212228-bib-0007){ref-type="ref"} they are often underused in this group worldwide.[8](#ehf212228-bib-0008){ref-type="ref"} The reason is most likely related to concerns that β‐blockers may induce bronchospasm in COPD patients. The National Institute for Health and Care Excellence and European Society of Cardiology guidelines state that COPD is not a contraindication for the use of β‐blockers, and mild deterioration in pulmonary function and symptoms should not indicate the necessity for prompt discontinuation.[9](#ehf212228-bib-0009){ref-type="ref"}, [10](#ehf212228-bib-0010){ref-type="ref"} Nonetheless, low‐dose initiation and gradual uptitration are recommended in the guidelines.[9](#ehf212228-bib-0009){ref-type="ref"}, [10](#ehf212228-bib-0010){ref-type="ref"} In Asia, ageing populations and large increases in cardiovascular risk factors have contributed to a high burden of HF.[11](#ehf212228-bib-0011){ref-type="ref"} Patients with HFrEF from Asia may differ in clinical characteristics from patients elsewhere.[12](#ehf212228-bib-0012){ref-type="ref"}, [13](#ehf212228-bib-0013){ref-type="ref"} The Asian Sudden Cardiac Death in Heart Failure (ASIAN‐HF) registry was established to bridge the knowledge gap regarding the burden associated with chronic HF in Asian patients. In the present study, we report data on co‐morbidities of Asian patients with HFrEF enrolled from 1 October 2012 to 31 December 2015, with special reference to COPD and its treatment.[14](#ehf212228-bib-0014){ref-type="ref"}, [15](#ehf212228-bib-0015){ref-type="ref"}

Methods {#ehf212228-sec-0006}
=======

Study design {#ehf212228-sec-0007}
------------

The ASIAN‐HF registry was a prospective observational registry of symptomatic patients with HFrEF from 44 centres in 11 Asian regions (China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand) that enrolled patients between 2010 and 2015. Detailed methods have been previously published.[14](#ehf212228-bib-0014){ref-type="ref"} HFrEF was defined as patients \>18 years of age with symptomatic HF (at least one episode of decompensated HF in the previous 6 months that resulted in a hospital admission or was treated in an outpatient clinic) and LV systolic dysfunction (ejection fraction ≤40% on baseline echocardiography).[14](#ehf212228-bib-0014){ref-type="ref"} Ethics approval was obtained from the local institutional review board of each participating centre, and the study complied with the Declaration of Helsinki.

For this study, patients from the ASIAN‐HF registry with both HF and COPD were identified, and health data including vital signs and other diagnosed illnesses were analysed. Heart rate was measured at rest using electrocardiography. Hypertension was defined as the presence of a clinical diagnosis of hypertension (blood pressure ≥ 140/90 mmHg) or treatment with anti‐hypertensive medications. Diabetes was defined as the presence of a clinical diagnosis of diabetes (fasting plasma glucose ≥ 7 mmol/L or random plasma glucose ≥ 11.1 mmol/L or HbA1C ≥ 6.5%) or treatment with anti‐diabetic therapy. COPD was diagnosed in accordance with the Global Initiative for Chronic Obstructive Lung Disease criteria.[16](#ehf212228-bib-0016){ref-type="ref"} The usage of β‐blocker was defined at first visit.

Statistical analyses {#ehf212228-sec-0008}
--------------------

The primary analysis compared the clinical characteristics of HF patients with or without COPD in the overall cohort. Secondary analyses were conducted in a 1:2 propensity‐matched cohort and the Japanese cohort separately. Propensity matching for age, sex, geographical region, income level, and ethnic group was performed to produce the matched cohort (with a ratio of COPD to non‐COPD patients of 1:2). Patients were categorized on the basis of geographic region of recruitment, income level, and ethnic group, with groups defined as follows: Geographic region (by United Nations; Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand, Malaysia, Philippines, Indonesia, Singapore)Income level (by World Health Organization; high: Japan, Singapore, Hong Kong, Taiwan, South Korea; middle: China, Malaysia, Thailand; low: Philippines, Indonesia, India)Ethnicity (Chinese, Indian, Malay, Japanese, Korean, Thai, and Indigenous Southeast Asians)

Continuous variables were expressed as mean ± standard deviation, while categorical variables were expressed as number (percentage). To compare baseline characteristics in HF patients with or without COPD, χ^2^ tests and independent *t*‐tests were used for categorical and continuous variables, respectively. Multivariable logistic regression to assess those factors associated with the diagnosis of COPD, including variables with *P*‐values \<0.10 in univariable analysis as well as clinical and demographic variables from a prior knowledge. A *P*‐value ≤0.05 was considered statistically significant. Stata software version 14 (StataCorp., TX) was used for statistical analyses.

Results {#ehf212228-sec-0009}
=======

Baseline characteristics of the overall population {#ehf212228-sec-0010}
--------------------------------------------------

In the overall HFrEF cohort, 434 (8.3%) patients had a diagnosis of COPD, whereas 4798 (91.7%) did not. *Table* [1](#ehf212228-tbl-0001){ref-type="table-wrap"} shows the clinical characteristics of the groups categorized by the presence or absence of COPD. There was signification variation in the prevalence of COPD by geographical region and income level (all *P* \< 0.05). The highest prevalence of COPD was found in Northeast Asians (11.0%), who were significantly older than patients in other areas (mean age: 62 ± 14 years vs. 58 ± 12 years in other regions), while COPD prevalence was lowest in South Asians (4.7%) (*Table* [*S1*](#ehf212228-supitem-0001){ref-type="supplementary-material"}). COPD was also more prevalent in high‐ and middle‐income regions than in low‐income regions (*Table* [*S1*](#ehf212228-supitem-0001){ref-type="supplementary-material"}). The prevalence of COPD varied widely among ethnicities, ranging from 17.0% in Filipinos to 5.2% in Indians ([*Table S2*](#ehf212228-supitem-0001){ref-type="supplementary-material"}). Overall, the COPD group was significantly older, had a greater severity of HF as assessed with the New York Heart Association (NYHA) classification, and had higher prevalence of renal artery stenosis and smoking than the non‐COPD group (all *P* \< 0.05). The most common presenting symptoms in the COPD group were breathlessness on exertion, orthopnoea, and paroxysmal nocturnal dyspnoea. No significant differences were found between the COPD and non‐COPD groups for body mass index, ischaemic aetiology, or the prevalence of hypertension, diabetes mellitus, and atrial fibrillation/flutter or echo parameters, including LV ejection fraction, LV end diastolic volume, LV end systolic volume, and left atrium volume. The average heart rate on electrocardiogram of the COPD group (83 ± 19 b.p.m.) was significantly higher than that of the non‐COPD group (81 ± 19 b.p.m.; *P* = 0.048). HF medications were significantly underused in the COPD group. Angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin receptor blockers (ARB) were used in 70.9% and 75.8% of patients in the COPD and non‐COPD groups, respectively (*P* = 0.028). Similarly, β‐blockers were used in 66.3% and 79.9% of patients in the COPD and non‐COPD groups, respectively (*P* \< 0.001). Conversely, the use of mineralocorticoid receptor antagonists and diuretics was approximately the same between the two groups. HF device therapy (defibrillator, pacemaker, or cardiac resynchronization therapy) was more frequently employed in the COPD group than in the non‐COPD group (20.1% vs. 13.8%, respectively, *P* \< 0.001), which might be attributed to a more severe HF condition assessed by the NYHA classification in the COPD group.

###### 

Baseline characteristics of heart failure patients with and without chronic obstructive pulmonary disease

                                            Overall cohort   1:2 matched[a](#ehf212228-note-0003){ref-type="fn"} cohort   Japanese cohort                                                                          
  ----------------------------------------- ---------------- ------------------------------------------------------------ ----------------- -------------- -------------- ---------- -------------- -------------- -------
  *N*                                       434 (8.3%)       4798 (91.7%)                                                                   410            820                       63 (11.8%)     471 (88.2%)    
  Demographics                                                                                                                                                                                                     
  Age (years)                               63.9 ± 13.7      59.3 ± 12.9                                                  \<0.001           63.9 ± 13.7    64.2 ± 12.7    0.666      68.5 ± 12.6    64.6 ± 13.7    0.033
  Male                                      347 (80.0)       3742 (78.0)                                                  0.343             330 (80.5)     666 (81.2)     0.758      50 (79.4)      363 (77.1)     0.683
  Geographical region                                                                                                     \<0.001                                         0.556                                    
  Northeast Asia                            181 (41.7)       1471 (30.7)                                                                    175 (42.7)     360 (43.9)                                              
  South Asia                                68 (15.7)        1368 (28.5)                                                                    60 (14.6)      134 (16.3)                                              
  Southeast Asia                            185 (42.6)       1959 (40.8)                                                                    175 (42.7)     326 (39.8)                                              
  Income level                                                                                                            \<0.001                                         0.547                                    
  High income                               218 (50.2)       2020 (42.1)                                                                    214 (52.2)     444 (54.2)                                              
  Middle income                             111 (25.6)       1077 (22.5)                                                                    103 (25.1)     183 (22.3)                                              
  Low income                                105 (24.2)       1701 (35.4)                                                                    93 (22.7)      193 (23.5)                                              
  Presenting characteristics                                                                                                                                                                                       
  NYHA class, I/II/III/IV (%)               11/45/33/11      13/53/28/6                                                   \<0.001           12/44/33/11    13/52/30/5     0.001      8/67/23/2      6/73/18/3      0.621
  Shortness of breath on exertion           349 (80.4)       3567 (74.4)                                                  0.005             328 (80.0)     608 (74.2)     0.023      45 (71.4)      343 (72.8)     0.815
  Shortness of breath at rest               104 (24.0)       860 (17.9)                                                   0.002             95 (23.2)      151 (18.4)     0.049      9 (14.3)       59 (12.5)      0.694
  Reduction in exercise tolerance           318 (73.3)       3346 (69.8)                                                  0.128             301 (73.4)     553 (67.5)     0.034      38 (60.3)      311 (66.0)     0.371
  Nocturnal cough                           115 (26.5)       841 (17.5)                                                   \<0.001           109 (26.6)     136 (16.6)     \<0.001    5 (7.9)        22 (4.7)       0.267
  Orthopnoea                                137 (31.6)       1046 (21.8)                                                  \<0.001           132 (32.2)     174 (21.2)     \<0.001    3 (4.8)        28 (5.9)       0.706
  Paroxysmal nocturnal dyspnoea             116 (26.7)       878 (18.3)                                                   \<0.001           112 (27.3)     156 (19.0)     0.001      3 (4.8)        21 (4.5)       0.913
  Angina                                    67 (15.5)        530 (11.1)                                                   0.006             62 (15.2)      93 (11.3)      0.057      2 (3.2)        6 (1.3)        0.243
  Systolic blood pressure (mmHg)            119.4 ± 19.0     118.3 ± 20.3                                                 0.317             119.3 ± 18.8   118.8 ± 19.9   0.688      114.2 ± 18.3   112.7 ± 19.7   0.571
  Diastolic blood pressure (mmHg)           71.4 ± 12.1      72.5 ± 12.6                                                  0.087             71.2 ± 12.1    71.7 ± 12.3    0.545      66.7 ± 11.3    66.1 ± 12.9    0.708
  Heart rate (b.p.m.)                       80.5 ± 15.0      79.6 ± 16.3                                                  0.275             80.2 ± 14.9    77.9 ± 15.5    0.015      72.5 ± 10.7    72.6 ± 14.5    0.937
  Body mass index (kg/m^2^)                 24.8 ± 6.2       24.9 ± 5.0                                                   0.709             24.8 ± 6.0     24.5 ± 4.9     0.403      23.4 ± 3.9     22.8 ± 4.2     0.255
  eGFR (mL/min/1.73 m^2^)                   63.8 ± 10.8      65.1 ± 28.6                                                  0.403             64.1 ± 30.4    63.1 ± 27.9    0.610      67.1 ± 32.9    65.0 ± 28.8    0.603
  LVEF (%)                                  27.8 ± 7.2       27.3 ± 7.0                                                   0.207             27.8 ± 7.1     28.2 ± 6.6     0.305      28.6 ± 7.5     27.9 ± 7.6     0.542
  Medical history                                                                                                                                                                                                  
  Aetiology HF, ischaemic                   213 (49.1)       2245 (46.8)                                                  0.389             201 (49.0)     418 (51.0)     0.734      16 (25.4)      129 (27.4)     0.373
  Ventricular tachycardia/fibrillation      44 (10.1)        362 (7.5)                                                    0.053             40 (9.8)       70 (8.6)       0.484      18 (28.6)      115 (24.4)     0.474
  Coronary artery disease                   214 (49.3)       2411 (50.3)                                                  0.698             200 (48.8)     457 (55.8)     0.020      23 (36.5)      172 (36.5)     0.999
  Atrial fibrillation/flutter               83 (19.1)        851 (17.7)                                                   0.472             79 (19.3)      188 (23.0)     0.139      22 (34.9)      183 (38.9)     0.547
  Hypertension                              236 (54.4)       2475 (51.6)                                                  0.274             227 (55.4)     467 (57.0)     0.581      31 (49.2)      226 (48.0)     0.855
  Diabetes                                  167 (38.5)       1948 (40.6)                                                  0.383             158 (38.5)     374 (45.7)     0.017      13 (20.6)      156 (33.1)     0.045
  Stroke                                    31 (7.1)         305 (6.4)                                                    0.522             30 (7.3)       58 (7.1)       0.880      7 (11.1)       51 (10.8)      0.946
  Peripheral arterial vascular disease      26 (6.0)         152 (3.2)                                                    0.002             25 (6.1)       55 (5.4)       0.606      3 (4.8)        17 (3.6)       0.651
  Renal artery stenosis                     10 (2.3)         36 (0.8)                                                     0.001             10 (2.4)       8 (0.1)        0.044      2 (3.2)        3 (0.6)        0.050
  Smoking, current or ex                    261 (60.1)       2093 (43.7)                                                  \< 0.001          254 (62.0)     388 (47.4)     \< 0.001   38 (60.3)      252 (53.6)     0.316
  Alcohol, current or ex                    153 (35.3)       1359 (28.4)                                                  0.001             156 (38.1)     234 (28.6)     0.001      31 (49.2)      200 (42.6)     0.317
  12‐lead ECG                                                                                                                                                                                                      
  ECG rhythm, SR/AF/others or unknown (%)   64/11/25         70/12/18                                                     \< 0.001          64/12/24       66/15/19       0.057      32/11/57       41/15/44       0.172
  ECG heart rate (b.p.m.)                   83.3 ± 18.9      81.3 ± 19.0                                                  0.048             83.3 ± 19.1    80.1 ± 18.8    0.007      74.7 ± 18.1    73.6 ± 15.9    0.616
  Left bundle brunch block                  63 (15.0)        628 (13.8)                                                   0.732             58 (14.6)      97 (12.5)      0.516      9 (14.8)       38 (8.1)       0.086
  Right bundle brunch block                 39 (10.5)        350 (8.7)                                                    0.247             35 (10.0)      60 (8.9)       0.566      6 (9.7)        41 (8.8)       0.811
  QRS duration (ms)                         117.6 ± 32.2     115.1 ± 32.4                                                 0.138             117.6 ± 32.0   116.8 ± 32.4   0.684      136.9 ± 37.4   128.3 ± 34.3   0.069
  Echocardiography                                                                                                                                                                                                 
  LV end diastolic volume (mL)              182.9 ± 78.0     179.7 ± 67.2                                                 0.460             182.1 ± 77.4   178.8 ± 66.1   0.538      202.0 ± 88.2   203.1 ± 72.7   0.916
  LV end systolic volume (mL)               133.5 ± 67.1     130.4 ± 57.4                                                 0.392             133.0 ± 67.0   126.4 ± 55.7   0.140      147.7 ± 80.2   141.6 ± 66.0   0.545
  LA volume (mL)                            75.1 ± 35.8      70.8 ± 42.3                                                  0.135             75.4 ± 36.0    78.8 ± 54.9    0.411      97.0 ± 42.9    96.4 ± 66.4    0.954
  ICD and medications                                                                                                                                                                                              
  ICD/pacemaker/CRT                         87 (20.1)        661 (13.8)                                                   \<0.001           83 (20.2)      154 (18.8)     0.546      42 (66.7)      242 (51.4)     0.022
  ICD/CRT                                   66 (15.2)        507 (10.6)                                                   0.003             62 (15.1)      119 (14.5)     0.782      33 (52.4)      220 (46.7)     0.397
  Pacemaker                                 21 (4.8)         154 (3.2)                                                    0.071             21 (5.1)       35 (4.3)       0.501      9 (14.3)       22 (4.7)       0.002
  ACE‐I or ARB                              292 (70.9)       3503 (75.8)                                                  0.028             292 (71.2)     605 (73.8)     0.341      48 (77.4)      386 (83.0)     0.278
  β‐Blockers                                273 (66.3)       3692 (79.9)                                                  \< 0.001          272 (66.3)     670 (81.7)     \< 0.001   59 (95.2)      423 (91.2)     0.287
  Diuretics                                 330 (80.1)       3772 (81.6)                                                  0.454             328 (80.0)     658 (80.2)     0.919      40 (64.5)      340 (73.1)     0.156
  Aldosterone antagonists                   240 (58.3)       2751 (59.5)                                                  0.619             239 (58.3)     479 (58.4)     0.967      34 (54.8)      270 (58.1)     0.629

ACE‐I, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SR, sinus rhythm. Mean ± standard deviation.

Propensity matched for age, sex, geographical region, income level, and ethnic group.

Independent correlates of chronic obstructive pulmonary disease {#ehf212228-sec-0011}
---------------------------------------------------------------

*Table* [2](#ehf212228-tbl-0002){ref-type="table-wrap"} shows the multivariable associations with COPD after adjustment for the variables listed. Compared with low‐income regions, the middle‐ and high‐income regions had 1.81 \[95% confidence interval (CI), 1.33--2.47\] and 1.82 (95% CI, 1.30--2.54) times higher odds of having COPD, respectively (*Table* [2](#ehf212228-tbl-0002){ref-type="table-wrap"}). COPD was significantly associated with older age, high NYHA classification, renal artery stenosis, smoking, and a high average heart rate on electrocardiography. The prevalence of COPD might lead to the underuse of β‐blockers in the overall cohort, but not in the Japanese cohort.

###### 

Multivariable associations with chronic obstructive pulmonary disease

  Characteristics           Whole cohort           Japanese cohort                          
  ------------------------- ---------------------- ----------------- ---------------------- -------
  Age (years)               1.031 (1.021, 1.040)   \<0.001            1.025 (1.003, 1.047)  0.026
  Income level                                                                              
  High income               1.82 (1.30, 2.54)      \<0.001                                  
  Middle income             1.81 (1.33, 2.47)      \<0.001                                  
  Low income                Reference                                                       
  NYHA                                                                                      
  Class III/IV              1.37 (1.08, 1.74)      0.010                                    
  Class I/II                Reference                                                       
  Diabetes                  0.79 (0.62, 1.00)      0.054               0.50 (0.26, 0.96)    0.038
  Renal artery stenosis     3.49 (1.60, 7.66)      0.002               6.12 (0.86, 43.44)   0.070
  Smoking, current or ex    2.27 (1.75, 2.95)      \< 0.001            1.29 (0.74, 2.26)    0.370
  ECG heart rate (b.p.m.)   1.007 (1.001, 1.013)   0.016                                    
  ACE‐I or ARB              0.93 (0.72, 1.20)      0.594                                    
  β‐Blockers                0.47 (0.37, 0.61)      \< 0.001            2.12 (0.63, 7.14)    0.228

ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; NYHA, New York Heart Association.

Adjusted for female, nocturnal cough, ventricular tachycardia/fibrillation, coronary artery disease, and variables listed.

Propensity‐matched and Japanese cohorts {#ehf212228-sec-0012}
---------------------------------------

Because of significant differences in the baseline characteristics, HFrEF patients were 1:2 matched into a COPD group (*n* = 410) and non‐COPD group (*n* = 820) using propensity matching for age, sex, geographical region, income level, and ethnic group as a secondary analysis (*Table* [1](#ehf212228-tbl-0001){ref-type="table-wrap"}). As noted in the overall cohort, the COPD group had a higher average heart rate and lower usage of β‐blockers than the non‐COPD group (83 ± 19 b.p.m. vs. 80 ± 19 b.p.m., *P* = 0.007; and 66.3% vs. 81.7%, *P* \< 0.001).

Among the Japanese cohort, usage of β‐blockers was remarkably high (COPD group: 95.2% vs. non‐COPD group: 91.2%, *P* = 0.287) and the average heart rate (COPD group: 75 ± 18 b.p.m. vs. non‐COPD group: 74 ± 16 b.p.m., *P* = 0.616) was lower than other cohort data (*Table* [1](#ehf212228-tbl-0001){ref-type="table-wrap"}). No significant differences were found between the COPD and non‐COPD groups with respect to other parameters in this cohort.

Proportion of cardioselective and non‐cardioselective β‐blocker treatment {#ehf212228-sec-0013}
-------------------------------------------------------------------------

*Table* [3](#ehf212228-tbl-0003){ref-type="table-wrap"} shows usage of cardioselective and non‐cardioselective β‐blocker treatment for the COPD and non‐COPD groups. In all cohorts, the non‐COPD group had a higher usage of carvedilol, a non‐cardioselective β‐blocker, than the COPD group. Whereas in the overall cohort and 1:2 matched cohort, cardioselective β‐blockers were used equally in the COPD and non‐COPD groups, in the Japanese cohort, the usage of cardioselective β‐blockers was twofold higher in the COPD group as compared with the non‐COPD group.

###### 

Proportion of cardioselective and non‐cardioselective β‐blocker treatment for heart failure patients with and without chronic obstructive pulmonary disease

                                                                                     Overall cohort   1:2 matched[a](#ehf212228-note-0006){ref-type="fn"} cohort   Japanese cohort                                                                  
  ---------------------------------------------------------------------------------- ---------------- ------------------------------------------------------------ ----------------- ------------ ------------ --------- ------------ ------------- ---------
  *N*                                                                                434 (8.3%)       4798 (91.7%)                                                                   410          820                    63 (11.8%)   471 (88.2%)   
  Any β‐blockers                                                                     273 (66.3)       3692 (79.9)                                                  \<0.001           272 (66.3)   669 (81.7)   \<0.001   59 (95.2)    423 (91.2)    0.287
  HF guidelines β‐blockers[b](#ehf212228-note-0007){ref-type="fn"}                   236 (57.3)       3200 (69.2)                                                  \<0.001           235 (57.3)   569 (69.5)   \<0.001   59 (95.2)    419 (90.1)    0.198
  Any cardioselective β‐blockers[c](#ehf212228-note-0008){ref-type="fn"}             153 (37.1)       1695 (36.7)                                                  0.849             152 (37.1)   311 (38.0)   0.759     30 (48.4)    108 (23.2)    \<0.001
  HF guidelines cardioselective β‐blockers[d](#ehf212228-note-0009){ref-type="fn"}   149 (36.2)       1651 (35.7)                                                  0.854             148 (36.1)   305 (37.2)   0.695     30 (48.4)    108 (23.2)    \<0.001
  Carvedilol only                                                                    89 (21.6)        1605 (34.7)                                                  \<0.001           89 (21.7)    277 (33.8)   \<0.001   30 (48.4)    319 (68.6)    0.002

Propensity matched for age, sex, geographical region, income level, and ethnic group.

Bisoprolol, metoprolol, nebivolol, and carvedilol.

Bisoprolol, metoprolol, nebivolol, and atenolol.

Bisoprolol, metoprolol, and nebivolol.

Discussion {#ehf212228-sec-0014}
==========

This analysis of the multi‐national ASIAN‐HF registry shows that a history of COPD was present in only 8.3% of the overall cohort, with significant variation in geography, regional income level, and ethnicity. The COPD group was significantly older, had higher NYHA classification scores, had higher average heart rate, and had a greater rate of HF device therapy than the non‐COPD group in the overall and matched cohorts. Furthermore, β‐blockers were significantly underused in the COPD group when compared with the non‐COPD group in both the overall and propensity‐matched cohorts. COPD was significantly correlated with the lower usage of β‐blockers in the overall and matched cohorts, but not in the Japanese cohort. The presence of COPD influenced the use of cardioselective β‐blockers in the Japanese cohort, with usage being twofold higher in COPD patients than in non‐COPD patients.

The high prevalence of smoking, coupled with an ageing population, threatens to further increase the burden of COPD. In addition, a previous report in Japan suggested that COPD is underdiagnosed.[17](#ehf212228-bib-0017){ref-type="ref"} The ASIAN‐HF registry found a lower rate of COPD diagnosis in the HF cohort than in other studies such as the Acute Decompensated Heart Failure National Registry[18](#ehf212228-bib-0018){ref-type="ref"} (27%), Get with the Guidelines registry[19](#ehf212228-bib-0019){ref-type="ref"} (26.7%), United States Veterans[20](#ehf212228-bib-0020){ref-type="ref"} (26.6%), and Olmsted County[21](#ehf212228-bib-0021){ref-type="ref"} (30%). Whether COPD is being underdiagnosed in these countries is unclear, but the findings suggest the need for enhanced screening efforts for COPD in Asians with HF.

COPD is a systemic inflammatory disease characterized by airflow limitation that is not fully reversible.[22](#ehf212228-bib-0022){ref-type="ref"} Up to one‐third of all deaths in patients with COPD can be attributed to cardiovascular disease, and for every 10% decrease in the forced expiratory volume in 1 s, the risk of cardiovascular mortality reportedly increases by 28%.[23](#ehf212228-bib-0023){ref-type="ref"} COPD is a key cause of β‐blocker underuse, largely owing to concerns regarding the precipitation of respiratory deterioration in HF patients.[4](#ehf212228-bib-0004){ref-type="ref"} Indeed, results from this contemporary study of the ASIAN‐HF registry showed significant underuse of β‐blockers in HF patients with COPD compared with those without COPD. Furthermore, the mean heart rate of COPD patients was significantly higher than that of non‐COPD patients. It is also possible that the relatively high heart rate observed in the COPD group was reflective of increased HF severity, as indicated by more severe NYHA classification relative to the non‐COPD group. Importantly, heart rate is directly related to overall risk of death, risk of cardiovascular death, and hospitalization risk in patients with HF,[24](#ehf212228-bib-0024){ref-type="ref"} while heart rate reduction is associated with improved outcomes.[25](#ehf212228-bib-0025){ref-type="ref"}

In the past, β‐blockers were thought to be potentially harmful in patients with COPD. However, several recent studies have demonstrated significant benefits of the use of β‐blockers in COPD patients.[26](#ehf212228-bib-0026){ref-type="ref"}, [27](#ehf212228-bib-0027){ref-type="ref"} One of these studies showed that β‐blockers might reduce the risk of mortality and respiratory exacerbation in patients with COPD.[26](#ehf212228-bib-0026){ref-type="ref"} Similarly, a systematic review and meta‐analysis of nine retrospective cohort studies reported a reduction in COPD‐related mortality of 31% with β‐blocker use.[28](#ehf212228-bib-0028){ref-type="ref"} Another study clearly demonstrated the safety of β‐blockers during COPD exacerbation.[8](#ehf212228-bib-0008){ref-type="ref"} Furthermore, the use of β‐blockers when started either at the time of hospital admission for myocardial infarction or before myocardial infarction has been shown to be associated with improved survival after myocardial infarction in patients with COPD.[29](#ehf212228-bib-0029){ref-type="ref"} We have also reported on the effectiveness of β‐blockers in Japanese HF patients with COPD.[30](#ehf212228-bib-0030){ref-type="ref"}

The ACE‐I or ARB was significantly underused in the COPD group in the overall cohort. The use of ACE‐I or ARB might be influenced by the discretion of the treating physicians, because the renal artery stenosis was significantly higher in the COPD group than in the non‐COPD group.

Evaluating prospective multi‐national data from the ASIAN‐HF registry has shown the important influence of both ethnicity and regional income level on the characteristics of HF patients with COPD. Our data suggest that the very high use of β‐blockers in Japanese HFrEF patients with COPD shows that these agents may be used safely in Asian patients with these two conditions. Further studies should evaluate long‐term data from the ASIAN‐HF registry for patients with COPD.

Study limitations {#ehf212228-sec-0015}
-----------------

Several limitations associated with the present study warrant consideration. These baseline registry data were cross‐sectional in nature, and we were unable to exclude the possibility of selection bias. Bias is inevitable in the selection of sites in each region, and the willingness of patients to participate in a prospective protocol influences enrolment. In previous objective data on the prevalence of COPD in Asia, the COPD prevalence rates were 6.3%.[31](#ehf212228-bib-0031){ref-type="ref"} According to the Global Burden of Disease Study, not only each region but also multi‐ethnicity in the same country influenced the prevalence rates of COPD.[32](#ehf212228-bib-0032){ref-type="ref"} Our results may therefore still underestimate the true burden of HF with COPD in Asia. Furthermore, the use of β‐blockers was left to the discretion of the treating physicians in each nation, and the β‐blocker doses and COPD grades were unclear. The usage rate of β‐blockers in each region might be influenced by different understanding of the safety and usefulness of the β‐blockers. This study cohort comprised only HFrEF patients in the ASIAN‐HF registry. Owing to the specificity of this population, β‐blockers should be considered as standard therapy. However, in patients with severe COPD, low‐dose initiation and gradual uptitration are recommended. In the overall cohort, the number of patients with COPD was relatively small. We therefore confirmed the results observed in the overall cohort using the propensity‐matched cohort as a way of minimizing confounding factors. It is noted that the prevalence of COPD in the Japanese cohort was low.

Conclusions {#ehf212228-sec-0016}
===========

In the Asian HF registry, COPD prevalence showed significant variation according to geography, regional income level, and ethnicity. The prevalence of COPD was strongly related to the underuse of β‐blockers, in patients with both HF and COPD.
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